Panagene PRODUCT


KRAS mutation is found in several cancers such as colorectal, lung, thyroid, pancreatic, cholangiocarcinoma. The KRAS mutations are often found on codons 12 and 13 of the exon 2, and lead to abnormal change of growth signal of the p21-ras protein. This abnormal change involved with cell growth and division may cause the process of cancer development by delivering the signal in excess. Existence of KRAS mutations is often related with a prognostic marker to drug response. For example, KRAS mutation is considered a strong prognostic marker for drug response of tyrosine kinase inhibitors such as gefitinib (Iressa) or erlotinib (Tarceva). Recently, KRAS mutation is often detected in colorectal cancer and may be related with drug response to cetuximab (Erbitux) or panitumumab (Vectibix) that is used for colon cancer therapy. Therefore, examination of KRAS mutation is needed to determine drug resistance of patients with colorectal or lung cancers and will be helpful for cancer therapies.

As this product is Medical Device, please read 'caution' and 'instruction' before use. Deliberation number : 2013-I10-11-2362

Product Name		Cat. No.		Size
PNAClamp™ KRAS Mutation Detection Kit (Ver. 4)		PNAC-1006 (40 mutations)		25 tests

· PNAC-1006 (40 mutations)

No.		Reagent		Exon		Amino Acid Change		Nucleotide Change		Cosmic No.
1		G12 PNA mix		2		p.G12S		c.34G>A		517

						p.G12R		c.34G>C		518

						p.G12C		c.34G>T		516

						p.G12D		c.35G>A		521

						p.G12A		c.35G>C		522

						p.G12V		c.35G>T		520

2		G13 PNA mix				p.G13S		c.37G>A		528

						p.G13R		c.37G>C		529

						p.G13C		c.37G>T		527

						p.G13D		c.38G>A		532

						p.G13A		c.38G>C		533

						p.G13V		c.38G>T		534

3		A59 PNA mix		3		p.A59S		c.175G>T		1235389

						p.A59T		c.175G>A		546

						p.A59E		c.175G>A		547

						p.A59G		c.175G>G		28518

						p.A59del		c.176_178delCAG		1667040

4		Q61 PNA mix				p.G60D		c.179G>A		87290

						p.G60A		c.179G>C		548

						p.G60V		c.179G>T		1667041

						p.G60G		c.180T>A		253757

						p.G60G		c.180T>C		1168050

						p.G61E		c.181C>G		550

						p.G61K		c.181C>A		549

						p.G61L		c.182A>T		553

						p.G61R		c.182A>G		552

						p.G61P		c.182A>C		551

						p.G61H		c.183A>T		555

						p.G61H		c.183A>C		554

5		K117 PNA mix		4		p.K117E		c.349A>G		1360831

						p.K117R		c.350A>G		1178068

						p.K117N		c.351A>C		19940

						p.K117N		c.351A>T		28519

6		K146 PNA mix				p.A146P		c.436G>C		19905

						p.A146T		c.436G>A		19404

						p.A146G		c.437C>G		1360829

						p.A146V		c.437C>T		19900

						p.A146A		c.438A>G		1360826

						p.A146A		c.438A>C		-

						p.A146A		c.438A>T		-

Cosmic No. is taken from the Catalogue of Somatic Mutations in Cancer. (http://www.sanger.ac.uk/genetics/CGP/cosmic)

Ready-to-use kit with result available within 3hours.

Compatible Real Time PCR
- ABI 7500, ABI 7900, ABI Step one plus, Bio-Rad CFX96, Light Cycler480 (Roche), Rotor-Gene Q.

Compatible Sample
- Fresh tissue, FFPE tissue.

Test Several Biomarkers in One Plate with same PCR conditions
- eg. EGFR+KRAS or EGFR+BRAF+PIK3CA in one plate

High Sensitivity, Specificity with small amount of DNA

As this product is Medical Device, please read 'caution' and 'instruction' before use.
Deliberation number : 2014-I10-26-0182

As this product is Medical Device, please read 'caution' and 'instruction' before use.
Deliberation number : 2013-I10-11-2362


1	Kwon et al., Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR and direct sequencing in formalin-fixed, paraffin-embedded tissue. Pathol Res Pract. 2011 15:207(12):762-768.
2	Jeong et al., Rapid and Sensitive Detection of KRAS Mutation by Peptide Nucleic Acid based Real-time PCR Clamping: A Comparison with Direct Sequencing between Fresh Tissue and Fomalin-fixed and Paraffin Embedded Tissue of Colorectal Cancer. The Korean Journal of Pathology: 2011 45:151-169.
3	Kobunai et al., The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: A comparison between direct sequencing and real-time PCR. Biochem Biophys Res Commun. 2010;395(1):158-162.
4	Chang et al., Fast simultaneous detection of K-RAS mutations in colorectal cance. BMC Cancer. 2009;11(9):179.
5	Beau-Faller et al., Detection of K-Ras mutations in tumor samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. Br J Cancer. 2009;100(6):985-992.
As this product is Medical Device, please read 'caution' and 'instruction' before use. Deliberation number : 2013-I10-11-2362